Abstract
Establishing causal links between inherited polymorphisms and cancer risk is challenging. Here, we focus on the single nucleotide polymorphism rs55705857 (A>G), which confers a 6-fold increased risk of IDH-mutant low-grade glioma (LGG) and is amongst the highest genetic associations with cancer. By fine-mapping the locus, we reveal that rs55705857 itself is the causal variant and is associated with molecular pathways that drive LGG. Mechanistically, we show that rs55705857 resides within a brain-specific enhancer, where the risk allele disrupts OCT2/4 binding, allowing increased interaction with the Myc promoter and increased Myc expression. To functionally test rs55705857, we generated an IDH1R132H-driven LGG mouse model and show that mutating the highly conserved, orthologous mouse rs55705857 locus dramatically accelerated tumor development from 463 to 172 days and increased penetrance from 30% to 75%. Overall, our work generates new LGG models and reveals mechanisms of the heritable predisposition to lethal glioma in ∼40% of LGG-patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
D.S. is a recipient of a Career Development Award from the HFSP (CDA00080/2015), S.L. is recipient of a Canadian Breast Cancer Fellowship (BC-F-16#31919). This work was conducted with support of the Ontario Institute for Cancer Research through funding provided by the Government of Ontario. Work at University of California, San Francisco was supported by the National Institutes of Health (grant numbers R01CA52689, P50CA097257, R01CA139020, R01CA119215, R01CA207360), as well as the loglio Collective, the Stanley D. Lewis and Virginia S. Lewis Endowed Chair in Brain Tumor Research (MW), the Robert Magnin Newman Endowed Chair in Neuro-oncology. R.B.J. and the work at Mayo was supported by NCI grants CA230712, P50 CA108961 and CA139020, the National Brain Tumor Society, the Loglio Collective, the Mayo Clinic, and the Ting Tsung and Wei Fong Chao family foundation. Work at Lawrence Berkeley National Laboratory was supported by National Institutes of Health grants R01HG003988 (to L.A.P.) and R00HG009682 (to E.Z.K.) and was performed under Department of Energy Contract DE-AC02-05CH11231, University of California.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Mayo Clinic gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE167806
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172391
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE172390
